English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Colon cancer is the third most lethal type of cancer in the world. Resistance to chemotherapy remains a serious barrier in the treatment of several forms of cancer, particularly colon cancer. Therefore, it is essential to develop alternative treatment methods. The docking score study of the aervine produced a low dock score for the 2BDF target compared to the 1IKN and 4OAR targets. Comparing the aervine to the reference compounds Capecitabine for 2BDF, Topotecan Hydrochloride for 1IKN and Tamoxifen for 4OAR, the binding affinity of the aervine was found to be higher. Further molecular dynamic simulation results for aervine and reference standard drugs for each cancer types reveals that aervine possess good binding affinity simulation trajectories towards all three cancer targets. The MTT assay revealed that aervine has a highest cytotoxic impact against a colorectal cancer cell line, with an IC 50  value of 122.12 ± 1.26µg/ ml. Aervine produces reactive oxygen species, induces caspase-3 pathway in SW480 cells, and promotes apoptosis. This research shows that aervine can be developed as a new 2BDF target inhibitor against colorectal cancer.

molecular simulation

Anti-cancer potentials of aervine validated through  in silico  molecular docking, dynamics simulations, pharmacokinetic prediction and  in vitro  assessment of caspase – 3 in SW480 cell line